ADALIMUMAB

adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes

ADALIMUMAB (9188N)

adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes
9188N
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe Crohn disease
Treatment phase: Initial 1 (new patient)

Restriction

Indication: Severe Crohn disease
Treatment phase: Initial 2 (change or recommencement of treatment after a break in targeted therapy of less than 12 months)

Restriction

Indication: Severe Crohn disease
Treatment phase: Initial 3 (recommencement of treatment after a break in targeted therapy of more than 12 months)

Restriction

Indication: Severe Crohn disease
Treatment phase: Balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 2 DPMQ: $495.79 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Amgevita
Hadlima
Hyrimoz